由于转移、复发和化疗耐药，结直肠癌（CRC）患者的预后仍然比预期差。结直肠癌干细胞（CRCSC）在肿瘤转移、复发和化疗耐药中发挥着至关重要的作用。然而，目前尚无基于CRCSCs相关基因的预后标志物可供临床使用。在这项研究中，采用单细胞转录组测序来区分 CRC 微环境中的癌症干细胞 (CSC)，并在单细胞水平分析其特性。随后，利用TCGA和GEO数据库的数据开发CRCSC相关基因的预后风险模型并验证其诊断性能。此外，还研究了风险模型中相关基因的功能富集、免疫反应和化疗药物敏感性。最后，风险模型中的关键基因RPS17被确定为潜在的预后标志物和治疗靶点，以供进一步综合研究。我们的研究结果为 CRC 的预后治疗提供了新的见解，并为系统、全面地了解 CRC 的发展提供了新的视角。© 2024。作者。

The prognosis for patients with colorectal cancer (CRC) remains worse than expected due to metastasis, recurrence, and resistance to chemotherapy. Colorectal cancer stem cells (CRCSCs) play a vital role in tumor metastasis, recurrence, and chemotherapy resistance. However, there are currently no prognostic markers based on CRCSCs-related genes available for clinical use. In this study, single-cell transcriptome sequencing was employed to distinguish cancer stem cells (CSCs) in the CRC microenvironment and analyze their properties at the single-cell level. Subsequently, data from TCGA and GEO databases were utilized to develop a prognostic risk model for CRCSCs-related genes and validate its diagnostic performance. Additionally, functional enrichment, immune response, and chemotherapeutic drug sensitivity of the relevant genes in the risk model were investigated. Lastly, the key gene RPS17 in the risk model was identified as a potential prognostic marker and therapeutic target for further comprehensive studies. Our findings provide new insights into the prognostic treatment of CRC and offer novel perspectives for a systematic and comprehensive understanding of CRC development.© 2024. The Author(s).